Search Results
Context Therapeutics webinar: Identification of CTIM-76, a CLDN6xCD3 bi-specific antibody
Context Therapeutics releases CTIM-76 Claudin 6 Therapeutic Antibody updates
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers
Context Therapeutics published in STAT Report on new cancer targets
Context Therapeutics highlights data on ONA-XR and CLDN6 at AACR 2022. With Martin Lehr.
Benefits of a clinical trial research - testicular cancer
Edinboro man cancer free after taking part in new clinical trial
Oh To Be Seventeen Again: Two (+) Decades of IL-17 Signaling by Dr. Sarah Gaffen
Biontech | CAR T | Cell Therapy
